Wednesday, October 24th, 3:30-4:55pm
Cancer is the leading cause of death in China, and novel oncology treatments are critical to preserving the nation’s public health. This panel will discuss trends in Chinese cancer research and survey the novel oncology drug R&D pipeline for China.
- Richard Yeh, MD, Head, China Healthcare Research, Citi Investment Research
- Guoqing Cao, PhD, Vice President & Global Head, Discovery Biology Division, Hengrui Pharmaceuticals
- Weiguo Su, PhD, EVP & Chief Scientific Officer, Hutchison Medi Pharma
- Yinxiang Wang, PhD, CEO & Chief Scientist, Zhejiang BetaPharma Co., Ltd.
- Jinzi J. Wu, PhD, Co-Founder, President, & CEO, Ascletis Inc.
Weiguo Su , PhD
Prior to joining HMP in 2005, Dr. Su spent fifteen years with Pfizer's US R&D organization. Dr. Su delivered several high quality new drug candidates during his time with Pfizer, most recently as a director in the Medicinal Chemistry Department. He received his PhD and post-doctoral fellowship in Chemistry from Harvard University under the guidance of Nobel Laureate Professor E. J. Corey, and his Bachelor's degree in Chemistry from Fudan University in Shanghai, China.
Yinxiang Wang, PhD
Dr. Wang was a postdoctal research fellow in molecular biophysics and biochemistry field at Yale University, from 1999 to 2002. In 2003, Dr. Wang returned to China and founded Beijing Noval Drug R&D Center of Zhejiang Beta Pharma Inc. Dr. Wang is also an Adjunct Professor at Drug Safety Evaluation Center of Chinese Academy of Medical Sciences.
Jinzi J. Wu, PhD
Dr. Jinzi J. Wu is Co-founder, President and CEO of Ascletis, Inc. He successfully completed $100M Series A financing in 2011, including a first tranche of $50M. He has assembled world-class team and investors to deliver the Company’s two pronged business strategy: near-term accelerated revenue generation and long-term value creation.
Prior to founding Ascletis, Dr. Wu was Vice President, HIV drug discovery performance unit and Head of infectious disease (ID) Discovery DMPK at GSK. He oversaw the global HIV drug discovery from target identification and lead optimization to the preclinical and clinical development. Over the last two years (2009 and 2010), under Dr. Wu’s leadership, his Unit delivered two phase II clinical drugs with the best-in-class potential and one phase I asset. In his role as Head of ID Discovery DMPK, he supported drug discovery in other therapeutic areas such as antibacterials.
Prior to his joining GSK in June, 2008, Dr. Wu was Vice President, Preclinical and Basic Research from 2004-2008 at Ambrilia Biopharma Inc (formerly Procyon Biopharma Inc), a biopharmaceutical company devoted to the development of anti-viral drugs. At Ambrilia, he oversaw and supported activities from the preclinical to clinical development. Dr. Wu was instrumental in the development of PPL-100, a clinical stage, next generation HIV protease inhibitor which was licensed to Merck in 2006 for $17 million upfront payment and milestone payments up to $215 million as well as significant royalties.
From 1992-2004, he held senior positions, with increasing responsibilities, at Biotech and Big Pharma including Immunex (now Amgen), Novartis and Hoechst Marion Roussel (now Sanofi-Aventis). Dr. Wu has 22 years R&D experience with Big Pharma, biotech and academic institutions. His experience in drug discovery and development involves in multiple therapeutic area with the focus on infectious diseases and oncology. He has published over 30 peer-reviewed articles and book chapters in prestigious journals and books. He is a co-inventor of a number of patent applications. He is also a regular speaker and chairperson at various US and international scientific conferences and delivered over 30 oral and poster presentations. He is a member of scientific committees of the international conferences including the International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies and a member of BayHelix. Dr. Wu received his PhD in Cancer Biology from the University of Arizona.
Richard Yeh, MD
Richard Yeh is the head of China healthcare research at the Citi Investment Research in Hong Kong, and he was ranked No.2 in both the 2012 and 2011 All-China Institutional Investor Survey, and #3 in All-Asia Institutional Investor Survey. Richard joined the Hong Kong-based China research team from Citi’s New York office, where he was a member of the U.S. large-cap biotechnology/healthcare team that was ranked No.4 in both 2008 and 2009 All-America Institutional Investor Survey. Before joining Wall Street, Richard gained extensive industry experience working at the global strategic marketing group at Wyeth Pharmaceuticals and conducted drug discovery research at Amgen.